---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034822"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:13:44.239690+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track

## Summary
- Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.
- ADHD portfolio net revenue $13.2M; ex-rebate up 10% YoY on price increases and improved gross-to-nets.
- Net income $2.0M ($0.21 basic EPS) vs $1.5M ($0.24) prior year; includes $3.8M derivative warrant gain.
- Adjusted EBITDA $(0.6)M includes EXXUA launch investments; cash $32.6M at Sep 30.
- EXXUA (gepirone) on track for commercial launch in Q4 2025; patent extended to Sep 2030; targeting $22B MDD market.

## SEC filing metadata
- accession: 0001437749-25-034822
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774925034822/0001437749-25-034822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774925034822/aytu20250924_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034822
- JSON: https://secwatch.observer/filing/0001437749-25-034822.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034822.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.